EyeGate Pharmaceuticals I... (EYEG)
Company Description
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye.
The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees.
The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye.
The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina.
The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Country | United States |
IPO Date | Feb 13, 2015 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 14 |
CEO | Stephen From |
Contact Details
Address: 271 Waverley Oaks Rd Ste 108 Waltham, MASSACHUSETTS United States | |
Website | http://www.eyegatepharma.com |
Stock Details
Ticker Symbol | EYEG |
Exchange | NASDAQ |
Fiscal Year | n/a |
Reporting Currency | USD |
CIK Code | 0001372514 |
CUSIP Number | 30233M503 |
ISIN Number | US30233M5031 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
No executives data available.Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 25, 2025 | 8-K | Current Report |
Mar 25, 2025 | S-8 | Filing |
Mar 25, 2025 | 10-K | Annual Report |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 10, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 10, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Jan 15, 2025 | 8-K | Current Report |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 14, 2024 | SCHEDULE 13G | Filing |